All news articles for March 2019

(Image: Getty/gradyreese)

Nightstar acquired by Biogen for $800m

By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

(Image: Getty/Shidlovski)

Genentech taps Halozyme’s tech in Herceptin Hylecta

By Maggie Lynch

Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.

(Image: Getty/Dr_Microbe)

Cell therapy market to triple in size by 2025

By Ben Hargreaves

The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.

Follow us

Products

View more

Webinars